The FDA said Abbott's BinaxNow and Quidel's QuickVue tests can now be sold without a prescription. Both tests were first OK'd last year but came with conditions that limited their use, including ...

Following the robust Q3 performance, Piper Sandler raised ABT’s price target to $133 from $131, keeping an Overweight rating ...